Researchers published a proof-of-principle paper in the journal Science Immunology demonstrating just how precision medicine for inflammatory skin rashes might work.
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.
For a type of wound that often plagues patients with diabetes, healing is no sure thing. IRP researchers recently identified why certain immune cells shift from helpful healers into saboteurs in those injuries.